


Product Name : QTX3034
Cat. No. : PC-28071
CAS No. : 2972625-49-1
Molecular Formula : C₃₅H₄₄ClFN₈O₂
Molecular Weight : 663.24
Target : Ras
Solubility : 10 mM in DMSO



CAS: 2972625-49-1

Biological Activity

QTX3034 is a potent, highly selective, orally bioavailable allosteric multi-**KRAS** inhibitor that is efficacious against a broad spectrum of the more common KRASG12D- and KRASG12V- mutated cancers in vitro and in vivo.

QTX3034 synergized with three different EGFR inhibitors (afatinib, cetuximab, erlotinib) to profoundly inhibit proliferation across multiple KRASG12D, KRASG12V, and KRASWT Amp mutant cell lines with strong ZIP synergy scores (>10).

Combination of QTX3034 and afatinib exhibited a markedly greater inhibitory effect on KRAS-mutant colony formation compared to the respective single agents.

QTX3034 induced a dose-dependent increase in EGFR phosphorylation in the KRASG12D- mutated cell line GP2D, while co-administration with afatinib robustly inhibited this EGFR activation.

References

Yang J. Zhang, et al. *Mol Cancer Ther* (2023) 22 (12_Supplement): LB_C09.

Patent WO2024187174 A2 2024-09-12.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com